Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit

Drug wholesalers are braced for bleak earnings for FY2016 as they see dwindling revenues from Gilead Sciences’ hepatitis C med Harvoni (ledipasvir + sofosbuvir), with No. 1 handler Suzuken’s Harvoni sales in July tumbling as much as 70% from the...read more